July 5, 2022

To
The Manager,
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

To
The Manager,
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050

Scrip Code - 532523
Scrip Symbol - Biocon

Subject: Company Statement

Dear Sir/Madam,

Please find enclosed a Company Statement titled “Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru”.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

Mayank Verma
Company Secretary and Compliance Officer
Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru

Bengaluru, India; July 5, 2022:

“Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), has received a EU GMP certificate from the Health Products Regulatory Authority (HPRA), Ireland, for its new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru, following a GMP inspection in April 2022.

The facility, spread across 340,000-square feet, will enhance our capabilities manifold to manufacture drug substance of our mAbs portfolio and will enable us to serve patients across the globe. This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing. Upon successful completion and qualification in 2021, it was awarded the Facility of the Year Award (FOYA) with a Honorable Mention, by the International Society for Pharmaceutical Engineering’s (ISPE).”

-- Company Spokesperson, Biocon Biologics.

For more information
seema.ahuja@biocon.com
+919972317792